Details

Autor(en) / Beteiligte

• Numakura, Kazuyuki
• Kobayashi, Mizuki
• Hatakeyama, Shingo
• Naito, Sei
• Horikawa, Yohei
• Tanaka, Toshikazu
• Kamada, Sachiko
• Muto, Yumina
• Yamamoto, Ryohei
• Koizumi, Atsushi
• Nara, Taketoshi
• Kanda, Sohei
• Saito, Mitsuru
• Narita, Shintaro
• Inoue, Takamitsu
• Shimoda, Naotake
• Tsuchiya, Norihiko
• Ohyama, Chikara
• Habuchi, Tomonori

Titel

Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutes

Ist Teil von

• International journal of clinical oncology, 2020-08, Vol.25 (8), p.1543-1550

Ort / Verlag

Singapore: Springer Singapore

Erscheinungsjahr

2020

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Purpose Despite nivolumab being increasingly used for treating metastatic renal cell carcinoma (mRCC), differing findings have been reported about its efficacy and safety in elderly patients. Thus, this study was aimed at evaluating nivolumab’s efficacy and safety for treating mRCC in Japanese patients aged ≥ 75 years. Methods From March 2013 to August 2019, 118 mRCC patients (89 men and 29 women) were treated with nivolumab. The objective response rates (ORRs) were compared between patients aged ≥ 75 and < 75 years. Progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were also compared between the two age-groups. Results The median follow-up duration after nivolumab initiation was 10 months. At the time of nivolumab initiation, 22 and 96 patients were aged ≥ 75 and < 75 years, respectively. Intergroup differences in patient characteristics except for age were not significant. Furthermore, intergroup differences in ORR (14 vs 23%; P  = 0.367), PFS (HR 0.74, 95% CI 0.37–1.51; P  = 0.414), and median OS (HR 1.29, 95% CI 0.68–2.46; P  = 0.433) were not significant. The incidence of nivolumab discontinuation due to AEs was significantly higher in the ≥ 75 years group (27% vs 7%; P  = 0.028), although the intergroup difference in the AE incidence rate was not significant (55% vs 43.8%; P  = 0.535). Conclusions Nivolumab’s effectiveness was comparable between the two patient groups, except for early AE-related discontinuation in the ≥ 75 year group.